2023 World Conference on Lung Cancer (Posters)-EP11.03. Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials

EP11.03. Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials - PDF(Slides)

Pdf Summary

This systematic review assessed the accuracy of using simple multiples of the median overall survival (mOS) to estimate survival scenarios in randomized trials of immunotherapy for advanced non-small cell lung cancer (NSCLC). The researchers identified 15 trials involving 13,184 participants and classified treatment groups based on whether they received chemotherapy combined with immunotherapy (9 trials), immunotherapy alone (6 trials), or chemotherapy alone (15 trials). The study found that for the worst-case scenario (90th percentile) and lower-typical scenario (75th percentile), simple multiples of the mOS accurately estimated survival in the chemotherapy-immunotherapy groups, but underestimated early deaths in the immunotherapy-alone groups. The accuracy was higher in the chemotherapy-alone groups. However, longer-term outcomes (25th and 10th percentiles) could not be estimated for most groups receiving immunotherapy due to insufficient follow-up. The authors concluded that while simple multiples of mOS were effective for estimating survival scenarios in chemotherapy-immunotherapy groups, longer follow-up is necessary to estimate survival beyond the mOS in immunotherapy trials. The study provides insights into the use of simple multiples of mOS in estimating survival scenarios and highlights the need for longer follow-up in immunotherapy trials to better understand long-term outcomes.

Asset Subtitle

Shalini Subramaniam

Meta Tag

Speaker Shalini Subramaniam

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

systematic review

accuracy

simple multiples

median overall survival

mOS

survival scenarios

randomized trials

immunotherapy

advanced non-small cell lung cancer

NSCLC